Reply to J.-E. Bibault et al, B. Tombal, and C. Cattrini et al
- PMID: 29856697
- DOI: 10.1200/JCO.2018.78.2151
Reply to J.-E. Bibault et al, B. Tombal, and C. Cattrini et al
Comment on
-
Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial.J Clin Oncol. 2018 Feb 10;36(5):446-453. doi: 10.1200/JCO.2017.75.4853. Epub 2017 Dec 14. J Clin Oncol. 2018. PMID: 29240541 Clinical Trial.
-
STOMPing Out Hormone-Sensitive Metastases With Local Therapies in Prostate Cancer.J Clin Oncol. 2018 Feb 10;36(5):435-437. doi: 10.1200/JCO.2017.76.5495. Epub 2017 Dec 14. J Clin Oncol. 2018. PMID: 29240543 Free PMC article. No abstract available.
-
Androgen-Deprivation Therapy Is More Than Palliation in Oligometastatic Prostate Cancer.J Clin Oncol. 2018 Aug 1;36(22):2350. doi: 10.1200/JCO.2018.78.0031. Epub 2018 Jun 1. J Clin Oncol. 2018. PMID: 29856689 No abstract available.
-
Treating Metastatic Prostate Cancer With Local Therapies: Is It Still Wishful Thinking?J Clin Oncol. 2018 Aug 1;36(22):2348-2349. doi: 10.1200/JCO.2017.77.5429. Epub 2018 Jun 1. J Clin Oncol. 2018. PMID: 29856690 No abstract available.
-
Metastasis-Targeted Therapy: Ready for Phase III?J Clin Oncol. 2018 Aug 1;36(22):2349-2350. doi: 10.1200/JCO.2017.77.5981. Epub 2018 Jun 1. J Clin Oncol. 2018. PMID: 29856694 No abstract available.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
